MannKind's to advance inhaled clofazimine to phase 2/3 for lung disease after promising early data

Jan. 23, 2023 6:35 AM ETMannKind Corporation (MNKD)By: Ravikash, SA News Editor1 Comment

Scientific Research Performed by a Female Chemist


MannKind (NASDAQ:MNKD) said clofazimine inhalation suspension (MNKD 101) will advance to an adaptive phase 2/3 study.

In addition, the company noted that a paper was published in the American Society for Microbiology journal Antimicrobial Agents and Chemotherapy

Recommended For You

Comments (1)

To ensure this doesn’t happen in the future, please enable Javascript and cookies in your browser.
Is this happening to you frequently? Please report it on our feedback forum.
If you have an ad-blocker enabled you may be blocked from proceeding. Please disable your ad-blocker and refresh.